Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Marker Therapeutics (MRKR) EBITDA (2016 - 2025)

Marker Therapeutics (MRKR) has disclosed EBITDA for 11 consecutive years, with $8.4 million as the latest value for Q4 2025.

  • Quarterly EBITDA rose 68.51% to $8.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$2.6 million through Dec 2025, down 14.02% year-over-year, with the annual reading at -$2.6 million for FY2025, 14.02% down from the prior year.
  • EBITDA for Q4 2025 was $8.4 million at Marker Therapeutics, up from -$2.1 million in the prior quarter.
  • The five-year high for EBITDA was $8.7 million in Q4 2023, with the low at -$10.9 million in Q2 2021.
  • Average EBITDA over 5 years is -$3.6 million, with a median of -$4.2 million recorded in 2023.
  • The sharpest move saw EBITDA surged 386.16% in 2023, then tumbled 84.61% in 2025.
  • Over 5 years, EBITDA stood at -$9.8 million in 2021, then skyrocketed by 68.88% to -$3.0 million in 2022, then soared by 386.16% to $8.7 million in 2023, then plummeted by 42.34% to $5.0 million in 2024, then surged by 68.51% to $8.4 million in 2025.
  • According to Business Quant data, EBITDA over the past three periods came in at $8.4 million, -$2.1 million, and -$4.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.